Corvus Pharmaceuticals, Inc. Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount
Corvus Pharmaceuticals, Inc. (CRVS) reported Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount of $27.14 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount · last filed 2026-08-06
- Corvus Pharmaceuticals, Inc. warrant down round feature decrease in net income loss to common shareholder amount for the quarter ending 2025-12-31 was $0.00.
- Corvus Pharmaceuticals, Inc. warrant down round feature decrease in net income loss to common shareholder amount for the quarter ending 2025-09-30 was $0.00.
- Corvus Pharmaceuticals, Inc. warrant down round feature decrease in net income loss to common shareholder amount for the quarter ending 2025-06-30 was $2.01M.
- Corvus Pharmaceuticals, Inc. warrant down round feature decrease in net income loss to common shareholder amount for the quarter ending 2025-03-31 was $25.13M.
- Corvus Pharmaceuticals, Inc. warrant down round feature decrease in net income loss to common shareholder amount for fiscal 2025 was $27.14M.
| Period end | Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount 3 month | Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount 6 month | Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount 9 month | Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | $2.01M derived: sum of 3 quarters · filed 2026-08-06 | $27.14M 10-K · filed 2026-03-12 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $2.01M derived: sum of 2 quarters · filed 2026-08-06 | $27.14M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $2.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $27.14M 10-Q · filed 2026-08-06 | ||
| 2025-03-31 | $25.13M 10-Q · filed 2026-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |